Watchdog suggests stem cell policies for state
By San Diego Union Tribune,
San Diego Union Tribune
| 01. 23. 2006
A taxpayer watchdog group is expected to release a report today outlining how leaders of the state's $3 billion stem cell initiative could develop policies to make stem-cell-based therapies affordable and accessible to Californians.
Leaders of the initiative known as Proposition 71 "must put the interests of taxpayers and patients ahead of private biotech companies who have (a) financial stake in the outcome," the Foundation for Taxpayer and Consumer Rights said in its report.
For example, a portion of the money the state raises by licensing scientific discoveries made with Proposition 71 funds should be used to make new therapies available to people who can't afford them, the foundation report states.
Biotechnology or pharmaceutical companies that develop therapies using science that results from Proposition 71 should be required to sell those therapies to California at their lowest price, the report states.
It also recommends that the institute reserve the right to keep a Proposition 71-funded discovery from being patented if it is determined that it would do more good by remaining in the public domain.
In addition, it suggests that...
Related Articles
By Ian Sample, The Guardian | 03.08.2024
Scientists are a step closer to making IVF eggs from patients’ skin cells after adapting the procedure that created Dolly the sheep, the first cloned mammal, more than two decades ago.
The work raises the prospect of older women being...
By Ramon Antonio Vargas, The Guardian | 02.28.2024
Doctors say a man in California who contracted blood cancer while living with HIV is in remission from both potentially fatal illnesses thanks to a treatment they are hailing as remarkable and encouraging.
Paul Edmonds is only the fifth-known person...
By Victoria Gray, Uduak Thomas, and Kevin Davies, The CRISPR Journal | 02.14.2024
In July 2019, medical staff in Nashville dosed the first U.S. patient in the exa-cel therapy trial, sponsored by Vertex Pharmaceuticals and CRISPR Therapeutics. That first patient was Victoria Gray, a mother of four from Forest, Mississippi, a sickle cell...
By Adam Zewe, MIT News | 02.07.2024
A tiny device built by scientists at MIT and the Singapore-MIT Alliance for Research and Technology could be used to improve the safety and effectiveness of cell therapy treatments for patients suffering from spinal cord injuries.
In cell therapy, clinicians...